Home LiteratureArticle Details
PMID: 1974272 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Lymphocyte-mediated activation of cultured endothelial cells (EC). CD4+ T cells inhibit EC class II MHC expression despite secreting IFN-gamma and increasing EC class I MHC and intercellular adhesion molecule-1 expression.

Journal of immunology (Baltimore, Md. : 1950) ·Vol. 145 ·No. 4 ·1990-08-15 ·Pages 1088-98

Doukas J, Pober JS

Abstract

Endothelial cells (EC) were cocultured with allogeneic PBL, CD4+ T cells, or CD8+ T cells, and the degrees of EC activation induced examined by determining patterns of endothelial class I and class II MHC and intercellular adhesion molecule-1 (ICAM-1) expression. Coculture with PBL or CD8+ T cells uniformly increases class I MHC and ICAM-1 expression on all EC within a culture, but induces class II MHC expression on only a subpopulation(s) of EC. This heterogeneous EC response to coculture contrasts with the uniform class II expression on all EC induced by IFN-gamma in replicate wells. CD4+ T cells, when compared to equal numbers of unfractionated PBL or CD8+ T cells, are more effective at increasing class I MHC and ICAM-1 but are unable to induce class II MHC expression. The failure of CD4+ T cells to induce EC class II MHC Ag is not due to insufficient activation of the T cells, as PHA-activated CD4+ T cells also do not induce significant class II expression. In addition, conditioned media (CM) from CD4+ T cell/EC contain greater levels of immunoreactive IFN-gamma than do CM from PBL/EC cocultures. Rather, CD4+ T cells appear to actively inhibit the induction of EC class II Ag but not class I or ICAM-1 by IFN-gamma. Inhibition occurs at the time of induction, as CD4+ T cells are not capable of down-regulating previously induced class II Ag. CM from CD4+/EC (but not PBL/EC) cocultures also inhibits IFN-gamma induction of EC class II MHC expression. The inhibitory activity is generated during CD4+ T cell-EC cell contact, and is enhanced by PHA. The inhibitory activity(ies) of the CD4+/EC-CM is as yet unidentified, and is only minimally reversible by cocktails of neutralizing antibodies directed against TNF-alpha, TNF-beta (lymphotoxin), IFN-alpha and IFN-beta. In conclusion, CD4+ and CD8+ T cells are each effective activators of EC, but the patterns of activation produced by these subsets are quite distinct, largely due to generation of a soluble inhibitor(s) of class II MHC induction during coculture of CD4+ T cells with EC.

MeSH Terms
Antigens, Differentiation, T-Lymphocyte/analysis CD4 Antigens/analysis CD4-Positive T-Lymphocytes/immunology CD8 Antigens Cell Adhesion Molecules/biosynthesis Cells, Cultured Endothelium, Vascular/immunology Histocompatibility Antigens Class I/biosynthesis Histocompatibility Antigens Class II/biosynthesis Humans Immune Sera/immunology Interferon-gamma/biosynthesis,pharmacology Phytohemagglutinins/pharmacology T-Lymphocytes, Regulatory/immunology
Chemicals
Antigens, Differentiation, T-Lymphocyte CD4 Antigens CD8 Antigens Cell Adhesion Molecules Histocompatibility Antigens Class I Histocompatibility Antigens Class II Immune Sera Phytohemagglutinins Interferon-gamma
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Doukas J
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
Pober J S
Article Info
Journal
Journal of immunology (Baltimore, Md. : 1950)
Abbr.
J Immunol
ISSN
0022-1767
Published
1990-08-15
Pages
1088-98
Language
English
Region
United States
NLM ID
2985117R
Subset
IM
Grants
NHLBI NIH HHS · 5T32HL07627 · United States
NHLBI NIH HHS · HL-36003 · United States
NHLBI NIH HHS · HL-36028 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com